AFM 11
Alternative Names: AFM11Latest Information Update: 30 Oct 2021
At a glance
- Originator Affimed Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD19 antigen modulators; CD3 antigen modulators; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 19 Jun 2019 Affimed terminates a phase I trial in Precursor B-cell lymphoblastic leukaemia-lymphoma in Austria, Czech republic, Israel, Poland and Russia due to its strategic decision to terminate the AFM 11 development(NCT02848911)
- 27 May 2019 Discontinued - Phase-I for Precursor B-cell lymphoblastic leukaemia-lymphoma (Second-line therapy or greater) in Czech Republic, Israel, Poland, Russia, Austria (IV)
- 16 May 2019 Affimed terminates a phase I dose-escalation trial in Non-Hodgkin lymphoma in USA, Czech Republic, Germany and Poland due to non-favorable risk/benefit profile with studied dosing regimen (NCT02106091)